NasdaqCM:DVAX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.1b

Last Updated

2021/07/25 22:36 UTC

Data Sources

Company Financials +

Executive Summary

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. More Details


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Dynavax Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DVAX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: DVAX's weekly volatility has decreased from 15% to 9% over the past year.


Market Performance


7 Day Return

0.7%

DVAX

3.3%

US Biotechs

2.0%

US Market


1 Year Return

6.6%

DVAX

23.6%

US Biotechs

39.1%

US Market

Return vs Industry: DVAX underperformed the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: DVAX underperformed the US Market which returned 39.1% over the past year.


Shareholder returns

DVAXIndustryMarket
7 Day0.7%3.3%2.0%
30 Day2.9%2.1%1.6%
90 Day-4.3%4.7%3.5%
1 Year6.6%6.6%25.4%23.6%41.3%39.1%
3 Year-30.1%-30.1%15.5%10.4%64.0%53.8%
5 Year-38.6%-38.6%48.4%36.5%123.9%99.0%

Long-Term Price Volatility Vs. Market

How volatile is Dynavax Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dynavax Technologies undervalued compared to its fair value and its price relative to the market?

37.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DVAX ($9.47) is trading below our estimate of fair value ($15.09)

Significantly Below Fair Value: DVAX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DVAX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DVAX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVAX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DVAX is overvalued based on its PB Ratio (10.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-5.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DVAX's earnings are forecast to decline over the next 3 years (-5% per year).

Earnings vs Market: DVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DVAX's is expected to become profitable in the next 3 years.

Revenue vs Market: DVAX's revenue (0.9% per year) is forecast to grow slower than the US market (9.3% per year).

High Growth Revenue: DVAX's revenue (0.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Dynavax Technologies performed over the past 5 years?

-0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DVAX is currently unprofitable.

Growing Profit Margin: DVAX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DVAX is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare DVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: DVAX has a negative Return on Equity (-61.9%), as it is currently unprofitable.


Financial Health

How is Dynavax Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DVAX's short term assets ($427.5M) exceed its short term liabilities ($109.4M).

Long Term Liabilities: DVAX's short term assets ($427.5M) exceed its long term liabilities ($280.9M).


Debt to Equity History and Analysis

Debt Level: DVAX's debt to equity ratio (180.3%) is considered high.

Reducing Debt: Insufficient data to determine if DVAX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DVAX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DVAX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Dynavax Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DVAX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DVAX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DVAX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Ryan Spencer (43 yo)

1.58yrs

Tenure

US$1,521,779

Compensation

Mr. Ryan Spencer serves as the Chief Executive Officer and Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologie...


CEO Compensation Analysis

Compensation vs Market: Ryan's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD2.44M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DVAX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: DVAX's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.


Top Shareholders

Company Information

Dynavax Technologies Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dynavax Technologies Corporation
  • Ticker: DVAX
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.085b
  • Shares outstanding: 114.59m
  • Website: https://www.dynavax.com

Number of Employees


Location

  • Dynavax Technologies Corporation
  • 2100 Powell Street
  • Suite 900
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Biography

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for preve...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/25 22:36
End of Day Share Price2021/07/23 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.